Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

NCT05255523 ·Status: UNKNOWN ·Phase: PHASE2

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

NCT03412383 ·Status: UNKNOWN ·Phase: PHASE2

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

NCT06254690 ·Status: RECRUITING ·Phase: PHASE2

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

NCT05880927 ·Status: RECRUITING ·Phase: PHASE2

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

NCT04034589 ·Status: UNKNOWN ·Phase: PHASE2

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

NCT05165225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

NCT04152057 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

NCT04917900 ·Status: UNKNOWN ·Phase: PHASE2

Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer

NCT01937689 ·Status: COMPLETED ·Phase: PHASE1

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

NCT06035016 ·Status: RECRUITING

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

NCT05429294 ·Status: UNKNOWN ·Phase: PHASE2

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

NCT06144944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

NCT05910398 ·Status: RECRUITING ·Phase: PHASE3

Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer

NCT04900311 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

NCT03923179 ·Status: UNKNOWN ·Phase: PHASE2

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

NCT04254263 ·Status: RECRUITING ·Phase: PHASE3

Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

NCT06754059 ·Status: RECRUITING

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

NCT05769751 ·Status: COMPLETED

Pyrotinib in HER2-positive Early Breast Cancer

NCT06718335 ·Status: NOT_YET_RECRUITING ·Phase: NA

A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

NCT03980054 ·Status: UNKNOWN ·Phase: PHASE3

Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP

NCT04929548 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

NCT05572645 ·Status: COMPLETED

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

NCT04033172 ·Status: UNKNOWN ·Phase: PHASE2

Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer

NCT04407988 ·Status: UNKNOWN ·Phase: PHASE2

Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

NCT07180082 ·Status: RECRUITING ·Phase: PHASE2